{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-042879","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2021-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.425488+00:00","generated_at":"2026-06-29T17:01:16.810026+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Finch Therapeutics Q2 net loss $15.2M; cash $168.1M; Takeda accelerates UC program","bullets":["Net loss $15.2M vs $8.3M YoY; R&D expense $14.0M, G&A $5.9M.","Cash and equivalents $168.1M at June 30, 2021, expected to fund operations into mid-2023.","Takeda elected to accelerate leadership of FIN-524/TAK-524 ulcerative colitis program.","CP101 open-label PRISM-EXT topline data from >130 patients expected H2 2021.","Topline data from FIN-211 in ASD and CP101 in chronic HBV expected H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-042879","json":"https://secwatch.observer/filing/0001564590-21-042879.json","markdown":"https://secwatch.observer/filing/0001564590-21-042879.md","text":"https://secwatch.observer/filing/0001564590-21-042879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000156459021042879/0001564590-21-042879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000156459021042879/fnch-8k_20210810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T17:01:16.810026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}